Infective endocarditis is a potentially lethal disease that has undergone major changes in both host and pathogen. The epidemiology of infective endocarditis has become more complex with today’s ...
4.3. Pulmonary Arterial Hypertension Associated With Congenital Heart Disease…2257 4.4. Pulmonary Arterial Hypertension Associated With Connective Tissue Diseases…2258 4.5. Pulmonary Arterial ...
From the Cardiac Ultrasound Laboratory (J.P.D., M.D.H., R.A.L.) and Surgical Cardiovascular Laboratory (J.L.G., S.S., B.J., J.T.), Massachusetts General Hospital ...
From the University Hospitals Case Medical Center, Harrington Heart and Vascular Institute, Cleveland, OH (A.B., J.C.F.); Department of Cardiovascular Medicine ...
From Departments of Physiology (V.L.A., T.M.H.E.) and Cardiology (V.L.A.), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the ...
From Department of Internal Medicine (T.T.T., J.V.C., D.E.S., J.F., A.R., K.A.E.), Division of Cardiology, University of Michigan Medical Center, Ann Arbor, Mich ...
A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac ...
From the Massachusetts General Hospital (L.H.S.), Boston; Michigan State University (M.J.R.), East Lansing; Duke Clinical Research Institute (W.P., D.O., X.Z., E.P ...
Originally published14 Sep 1999https://doi.org/10.1161/01.CIR.100.11.1253Circulation. 1999;100:1253–1258 This report summarizes our current understanding of how ...
Paclitaxel-containing devices (PTXDs) significantly reduce reintervention in patients with symptomatic femoropopliteal peripheral artery disease. A recent aggregate-data meta-analysis reported ...
From the University of Arizona (F.I.M., D.S., K.G.), Tucson, Ariz; The Heart Hospital, London, United Kingdom (W.J.M.); University of Padua Medical School, Padua ...
4.3. Initial Antiplatelet/Anticoagulant Therapy in Patients With Definite or Likely NSTE-ACS 2365 4.3.1. Initial Oral and Intravenous Antiplatelet Therapy in Patients ...